Experimental Hematology
Volume 30, Issue 10 , Pages 1185-1192 , October 2002

Marked improvement of thrombocytopenia in a murine model of idiopathic thrombocytopenic purpura by pegylated recombinant human megakaryocyte growth and development factor

  • Kazunori Shibuya

      Affiliations

    • Pharmaceutical Development Laboratory, Kirin Brewery Company, Ltd., Gunma, Japan
    • ,
  • Tomoaki Kuwaki

      Affiliations

    • Pharmaceutical Development Laboratory, Kirin Brewery Company, Ltd., Gunma, Japan
    • ,
  • Emiko Tahara

      Affiliations

    • Pharmaceutical Development Laboratory, Kirin Brewery Company, Ltd., Gunma, Japan
    • ,
  • Chizuru Yuki

      Affiliations

    • Pharmaceutical Development Laboratory, Kirin Brewery Company, Ltd., Gunma, Japan
    • ,
  • Hiromichi Akahori

      Affiliations

    • Pharmaceutical Development Laboratory, Kirin Brewery Company, Ltd., Gunma, Japan
    • ,
  • Takashi Kato

      Affiliations

    • Pharmaceutical Research Laboratory, Kirin Brewery Company, Ltd., Gunma, Japan
    • ,
  • Hiroshi Miyazaki

      Affiliations

    • Corresponding Author InformationOffprint requests to: Hiroshi Miyazaki, Ph.D., Pharmaceutical Development Laboratory, Kirin Brewery Company, Ltd., 3 Miyahara-cho, Takasaki, Gunma 370-1295, Japan
    • Pharmaceutical Development Laboratory, Kirin Brewery Company, Ltd., Gunma, Japan

Received 5 March 2002 ,Revised 11 June 2002 ,Accepted 13 June 2002.

References 

  1. de Sauvage FJ, Hass PE, Spencer SD, et al.  Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533
  2. Kaushansky K, Lok S, Holly RD, et al.  Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369:568
  3. Bartley TD, Bogenberger J, Hunt P, et al.  Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77:1117
  4. Kato T, Ogami K, Shimada Y, et al.  Purification and characterization of thrombopoietin. J Biochem. 1995;118:229
  5. Kuter DL, Beeler DL, Rosenberg RD. The purification of megapoietin (A physiological regulator of megakaryocytopoiesis). Proc Natl Acad Sci U S A. 1994;91:11104
  6. Kaushansky K, Broudy VC, Lin N, et al.  Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci U S A. 1995;92:3234
  7. Horie K, Miyazaki H, Hagiwara T, et al.  Action of thrombopoietin at the megakaryocyte progenitor cell level is critical for the subsequent proplatelet production. Exp Hematol. 1997;25:169
  8. Farese A, Hunt P, Boone T, MacVittie T. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood. 1995;86:54
  9. Kabaya K, Akahori H, Shibuya K, et al.  In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. Stem Cells. 1996;14:651
  10. Hokom MM, Lacey D, Kinstler OB, et al.  Pegylated recombinant human megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood. 1995;86:4486
  11. Shibuya K, Akahori H, Takahashi K, et al.  Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice. Blood. 1998;91:37
  12. Basser RL, Rasko JEJ, Clarke K, et al.  Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet. 1996;348:1279
  13. Harker LA, Roskos LK, Marzec RA, et al.  Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood. 2000;95:2514
  14. Fanucchi M, Glaspy J, Crawford J, et al.  Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997;336:404
  15. Basser RL, Rasko JEJ, Clarke K, et al.  Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89:3118
  16. Komatsu N, Okamoto T, Yoshida T, et al.  Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (PLT) in patients (pts) with aplastic anemia (AA) and myelodysplastic syndrome (MDS). Blood. 2000;96:296a; (abstr)
  17. Kuter DJ, Goodnough LT, Romo J, et al.  Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood. 2001;98:1339
  18. Li J, Yang C, Xia Y, et al.  Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241
  19. Karpatkin S. Autoimmune thrombocytopenic purpura. Blood. 1980;56:329
  20. McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1981;304:1135
  21. Berchtold P, McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood. 1989;74:2309
  22. Imbach P, Barandun S, D'Appuzo V, et al.  High dose intravenous gamma globulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228
  23. Bussel JB, Mukherjee R, Stone AJ. A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol. 2001;66:172
  24. Kosugi S, Kurata Y, Tomiyama Y, et al.  Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol. 1996;93:704
  25. Chang M, Suen Y, Meng G, et al.  Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia (insight into the regulation of platelet production). Blood. 1996;88:3354
  26. Ikehara S, Mizutani H, Kurata Y. Autoimmune thrombocytopenic purpura. Crit Rev Oncol Hematol. 1995;19:33
  27. Mizutani H, Furubayashi T, Kuriu A, et al.  Analyses of thrombocytopenia in idiopathic thrombocytopenic purpura-prone mice by platelet transfer experiments between (NZW × BXSB) F1 and normal mice. Blood. 1990;75:1809
  28. Nishiyama U, Morita H, Torii Y, et al.  Platelets exposed to elevated levels of endogenous thrombopoietin in vivo have a reduced response to megakaryocyte growth and development factor. Thromb Haemost. 2001;85:152
  29. Ault KA, Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol. 1995;23:996
  30. Oyaizu N, Yasumizu R, Miyama-Inaba M, et al.  (NZW × BXSB)F1 mouse. A new animal model of idiopathic thrombocytopenic purpura. J Exp Med. 1988;167:2017
  31. Carver-Moore K, Broxmeyer HE, Luoh S-M, et al.  Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood. 1996;88:803
  32. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-Mpl. Blood. 1996;87:2162
  33. Harker LA, Marzec UM, Novembre F, et al.  Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor. Blood. 1998;91:4427
  34. Harker LA, Carter RA, Marzec UM, et al.  Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy. Blood. 1998;92:707a; (abstr)

PII: S0301-472X(02)00898-6

Experimental Hematology
Volume 30, Issue 10 , Pages 1185-1192 , October 2002

Article Tools

* Image Usage & Resolution